Loading…

Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells

Abstract This study was designed to determine the ideal manner (schedule and duration) of intravesical chemotherapy using pirarubicin (THP). At first, T-24 cancer cells were treated with 50, 100, 150, and 200 μg/ml THP for 10, 30 and 60 min. Following the first exposure, at various intervals (3, 6,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2011, Vol.17 (1), p.11-16
Main Authors: Maruyama, Takuo, Higuchi, Yoshihide, Suzuki, Toru, Qiu, Jun, Yamamoto, Shingo, Shima, Hiroki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93
cites cdi_FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93
container_end_page 16
container_issue 1
container_start_page 11
container_title Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
container_volume 17
creator Maruyama, Takuo
Higuchi, Yoshihide
Suzuki, Toru
Qiu, Jun
Yamamoto, Shingo
Shima, Hiroki
description Abstract This study was designed to determine the ideal manner (schedule and duration) of intravesical chemotherapy using pirarubicin (THP). At first, T-24 cancer cells were treated with 50, 100, 150, and 200 μg/ml THP for 10, 30 and 60 min. Following the first exposure, at various intervals (3, 6, 12, and 24 h), a second exposure to THP was performed under the same condition in vitro. The cell viability was measured by XTT assay. Further, the cells were scanned with a laser scanning cytometer (LSC) and DNA histograms were analyzed to evaluate the cell-cycle components. A single exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth for 30 min with 100 μg/ml and higher concentrations of THP; for example, the cell viability was reduced to 15, 2, and 0% by incubating cells with 100, 150, and 200 μg/ml of THP, respectively, whereas it was 49% with 50 μg/ml THP. Double exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth than single treatment at all intervals. LSC assay demonstrated a higher sub-G1 peak after double treatment with THP when compared with that after a single treatment. Similar cytotoxic effects following double treatment with THP were observed on other bladder cancer cell lines (UMUC3, TCCSUP, 5637, and 253J cells) in vitro. In conclusion, the double short-term exposure to bladder cancer cells by THP has more remarkable cytotoxic effects than the single exposure in vitro.
doi_str_mv 10.1007/s10156-010-0088-y
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_851475237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X11705359</els_id><sourcerecordid>851475237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93</originalsourceid><addsrcrecordid>eNp9kk-L1TAUxYMozh_9AG4kO1fRmzZJWwRBRh2FAReO4C6kye17GfuaZ5IO029vSkcFF7O6Ifeck5sfl5AXHF5zgOZN4sClYsCBAbQtWx6RUy7qhjVNC4_LuRac1RX_cULOUroB4I1s26fkpAJVrrv2lOw-hLkfkaZ9iJllf0CKd8eQ5og0B3r00cS599ZP9BiDmy0muve7PUZqlxxyuCu9vFCzM35KmV5XgvajcW4VmMmuBccxPSNPBjMmfH5fz8n3Tx-vLz6zq6-XXy7eXzErVZeZGKyxvQJwfBAVutoOleoAexTIO-GMVHZQreoHMXCnJIBVlhvljOvlgF19Tl5tuWXaXzOmrA8-rROYCcOcdCu5aGRVN0XJN6WNIaWIgz5GfzBx0Rz0ildveHXBq1e8eimel_fpc39A99fxh2cRVJsglda0w6hvwhyn8uMHU99uJixgbn0xJeuxsHM-os3aBf-g-91_bjv6yVsz_sQF07_3dao06G_rUqw7wXkDspZd_Rv8G7E1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>851475237</pqid></control><display><type>article</type><title>Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells</title><source>Elsevier</source><creator>Maruyama, Takuo ; Higuchi, Yoshihide ; Suzuki, Toru ; Qiu, Jun ; Yamamoto, Shingo ; Shima, Hiroki</creator><creatorcontrib>Maruyama, Takuo ; Higuchi, Yoshihide ; Suzuki, Toru ; Qiu, Jun ; Yamamoto, Shingo ; Shima, Hiroki</creatorcontrib><description>Abstract This study was designed to determine the ideal manner (schedule and duration) of intravesical chemotherapy using pirarubicin (THP). At first, T-24 cancer cells were treated with 50, 100, 150, and 200 μg/ml THP for 10, 30 and 60 min. Following the first exposure, at various intervals (3, 6, 12, and 24 h), a second exposure to THP was performed under the same condition in vitro. The cell viability was measured by XTT assay. Further, the cells were scanned with a laser scanning cytometer (LSC) and DNA histograms were analyzed to evaluate the cell-cycle components. A single exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth for 30 min with 100 μg/ml and higher concentrations of THP; for example, the cell viability was reduced to 15, 2, and 0% by incubating cells with 100, 150, and 200 μg/ml of THP, respectively, whereas it was 49% with 50 μg/ml THP. Double exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth than single treatment at all intervals. LSC assay demonstrated a higher sub-G1 peak after double treatment with THP when compared with that after a single treatment. Similar cytotoxic effects following double treatment with THP were observed on other bladder cancer cell lines (UMUC3, TCCSUP, 5637, and 253J cells) in vitro. In conclusion, the double short-term exposure to bladder cancer cells by THP has more remarkable cytotoxic effects than the single exposure in vitro.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1007/s10156-010-0088-y</identifier><identifier>PMID: 20632198</identifier><language>eng</language><publisher>Japan: Elsevier Ltd</publisher><subject>Antineoplastic Agents - administration &amp; dosage ; Apoptosis - drug effects ; Bladder cancer ; Cell Cycle - drug effects ; Cell Line, Tumor ; Cell Survival - drug effects ; Dose-Response Relationship, Drug ; Doxorubicin - administration &amp; dosage ; Doxorubicin - analogs &amp; derivatives ; Drug Administration Schedule ; Hematology, Oncology and Palliative Medicine ; Humans ; Infectious Diseases ; Intravesical chemotherapy ; Laser Scanning Cytometry ; Medical Microbiology ; Medicine ; Medicine &amp; Public Health ; Neoplasm Staging ; Original Article ; Pirarubicin ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - pathology ; Virology</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Vol.17 (1), p.11-16</ispartof><rights>Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>2011 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93</citedby><cites>FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20632198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maruyama, Takuo</creatorcontrib><creatorcontrib>Higuchi, Yoshihide</creatorcontrib><creatorcontrib>Suzuki, Toru</creatorcontrib><creatorcontrib>Qiu, Jun</creatorcontrib><creatorcontrib>Yamamoto, Shingo</creatorcontrib><creatorcontrib>Shima, Hiroki</creatorcontrib><title>Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><addtitle>J Infect Chemother</addtitle><description>Abstract This study was designed to determine the ideal manner (schedule and duration) of intravesical chemotherapy using pirarubicin (THP). At first, T-24 cancer cells were treated with 50, 100, 150, and 200 μg/ml THP for 10, 30 and 60 min. Following the first exposure, at various intervals (3, 6, 12, and 24 h), a second exposure to THP was performed under the same condition in vitro. The cell viability was measured by XTT assay. Further, the cells were scanned with a laser scanning cytometer (LSC) and DNA histograms were analyzed to evaluate the cell-cycle components. A single exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth for 30 min with 100 μg/ml and higher concentrations of THP; for example, the cell viability was reduced to 15, 2, and 0% by incubating cells with 100, 150, and 200 μg/ml of THP, respectively, whereas it was 49% with 50 μg/ml THP. Double exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth than single treatment at all intervals. LSC assay demonstrated a higher sub-G1 peak after double treatment with THP when compared with that after a single treatment. Similar cytotoxic effects following double treatment with THP were observed on other bladder cancer cell lines (UMUC3, TCCSUP, 5637, and 253J cells) in vitro. In conclusion, the double short-term exposure to bladder cancer cells by THP has more remarkable cytotoxic effects than the single exposure in vitro.</description><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Apoptosis - drug effects</subject><subject>Bladder cancer</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Doxorubicin - analogs &amp; derivatives</subject><subject>Drug Administration Schedule</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Intravesical chemotherapy</subject><subject>Laser Scanning Cytometry</subject><subject>Medical Microbiology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neoplasm Staging</subject><subject>Original Article</subject><subject>Pirarubicin</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Virology</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kk-L1TAUxYMozh_9AG4kO1fRmzZJWwRBRh2FAReO4C6kye17GfuaZ5IO029vSkcFF7O6Ifeck5sfl5AXHF5zgOZN4sClYsCBAbQtWx6RUy7qhjVNC4_LuRac1RX_cULOUroB4I1s26fkpAJVrrv2lOw-hLkfkaZ9iJllf0CKd8eQ5og0B3r00cS599ZP9BiDmy0muve7PUZqlxxyuCu9vFCzM35KmV5XgvajcW4VmMmuBccxPSNPBjMmfH5fz8n3Tx-vLz6zq6-XXy7eXzErVZeZGKyxvQJwfBAVutoOleoAexTIO-GMVHZQreoHMXCnJIBVlhvljOvlgF19Tl5tuWXaXzOmrA8-rROYCcOcdCu5aGRVN0XJN6WNIaWIgz5GfzBx0Rz0ildveHXBq1e8eimel_fpc39A99fxh2cRVJsglda0w6hvwhyn8uMHU99uJixgbn0xJeuxsHM-os3aBf-g-91_bjv6yVsz_sQF07_3dao06G_rUqw7wXkDspZd_Rv8G7E1</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Maruyama, Takuo</creator><creator>Higuchi, Yoshihide</creator><creator>Suzuki, Toru</creator><creator>Qiu, Jun</creator><creator>Yamamoto, Shingo</creator><creator>Shima, Hiroki</creator><general>Elsevier Ltd</general><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells</title><author>Maruyama, Takuo ; Higuchi, Yoshihide ; Suzuki, Toru ; Qiu, Jun ; Yamamoto, Shingo ; Shima, Hiroki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Apoptosis - drug effects</topic><topic>Bladder cancer</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Doxorubicin - analogs &amp; derivatives</topic><topic>Drug Administration Schedule</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Intravesical chemotherapy</topic><topic>Laser Scanning Cytometry</topic><topic>Medical Microbiology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neoplasm Staging</topic><topic>Original Article</topic><topic>Pirarubicin</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maruyama, Takuo</creatorcontrib><creatorcontrib>Higuchi, Yoshihide</creatorcontrib><creatorcontrib>Suzuki, Toru</creatorcontrib><creatorcontrib>Qiu, Jun</creatorcontrib><creatorcontrib>Yamamoto, Shingo</creatorcontrib><creatorcontrib>Shima, Hiroki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maruyama, Takuo</au><au>Higuchi, Yoshihide</au><au>Suzuki, Toru</au><au>Qiu, Jun</au><au>Yamamoto, Shingo</au><au>Shima, Hiroki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><stitle>J Infect Chemother</stitle><addtitle>J Infect Chemother</addtitle><date>2011</date><risdate>2011</risdate><volume>17</volume><issue>1</issue><spage>11</spage><epage>16</epage><pages>11-16</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Abstract This study was designed to determine the ideal manner (schedule and duration) of intravesical chemotherapy using pirarubicin (THP). At first, T-24 cancer cells were treated with 50, 100, 150, and 200 μg/ml THP for 10, 30 and 60 min. Following the first exposure, at various intervals (3, 6, 12, and 24 h), a second exposure to THP was performed under the same condition in vitro. The cell viability was measured by XTT assay. Further, the cells were scanned with a laser scanning cytometer (LSC) and DNA histograms were analyzed to evaluate the cell-cycle components. A single exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth for 30 min with 100 μg/ml and higher concentrations of THP; for example, the cell viability was reduced to 15, 2, and 0% by incubating cells with 100, 150, and 200 μg/ml of THP, respectively, whereas it was 49% with 50 μg/ml THP. Double exposure of T-24 cells to THP resulted in significantly higher inhibition of cell growth than single treatment at all intervals. LSC assay demonstrated a higher sub-G1 peak after double treatment with THP when compared with that after a single treatment. Similar cytotoxic effects following double treatment with THP were observed on other bladder cancer cell lines (UMUC3, TCCSUP, 5637, and 253J cells) in vitro. In conclusion, the double short-term exposure to bladder cancer cells by THP has more remarkable cytotoxic effects than the single exposure in vitro.</abstract><cop>Japan</cop><pub>Elsevier Ltd</pub><pmid>20632198</pmid><doi>10.1007/s10156-010-0088-y</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1341-321X
ispartof Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Vol.17 (1), p.11-16
issn 1341-321X
1437-7780
language eng
recordid cdi_proquest_miscellaneous_851475237
source Elsevier
subjects Antineoplastic Agents - administration & dosage
Apoptosis - drug effects
Bladder cancer
Cell Cycle - drug effects
Cell Line, Tumor
Cell Survival - drug effects
Dose-Response Relationship, Drug
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Drug Administration Schedule
Hematology, Oncology and Palliative Medicine
Humans
Infectious Diseases
Intravesical chemotherapy
Laser Scanning Cytometry
Medical Microbiology
Medicine
Medicine & Public Health
Neoplasm Staging
Original Article
Pirarubicin
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - pathology
Virology
title Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Double%20short-time%20exposure%20to%20pirarubicin%20produces%20higher%20cytotoxicity%20against%20T24%20bladder%20cancer%20cells&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Maruyama,%20Takuo&rft.date=2011&rft.volume=17&rft.issue=1&rft.spage=11&rft.epage=16&rft.pages=11-16&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1007/s10156-010-0088-y&rft_dat=%3Cproquest_cross%3E851475237%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c569t-4fcacb600d1f42ed3cf2690ebe4e194da56cf686bf4f1d6500c6c1a6dadb5fe93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=851475237&rft_id=info:pmid/20632198&rfr_iscdi=true